Untch Michael, Würstlein Rachel, Marschner Norbert, Lüftner Diana, Augustin Doris, Briest Susanne, Ettl Johannes, Haidinger Renate, Müller Lothar, Müller Volkmar, Ruckhäberle Eugen, Harbeck Nadia, Thomssen Christoph
Klinik für Gynäkologie, HELIOS Klinikum Berlin-Buch, Berlin, Germany; Writing Committee.
Brustzentrum und CCC München, Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Germany; Writing Committee.
Geburtshilfe Frauenheilkd. 2018 May;78(5):469-480. doi: 10.1055/a-0594-2243. Epub 2018 Jun 4.
The fourth international advanced breast cancer consensus conference (ABC4) on the diagnosis and treatment of advanced breast cancer (ABC) headed by Professor Fatima Cardoso was once again held in Lisbon on November 2 - 4, 2017. To simplify matters, the abbreviation ABC will be used hereinafter in the text. In clinical practice, the abbreviation corresponds to metastatic breast cancer or locally far-advanced disease. This year the focus was on new developments in the treatment of ABC. Topics discussed included the importance of CDK4/6 inhibition in hormone receptor (HR)-positive ABC, the use of dual antibody blockade to treat HER2-positive ABC, PARP inhibition in triple-negative ABC and the potential therapeutic outcomes. Another major area discussed at the conference was BRCA-associated breast cancer, the treatment of cerebral metastasis, and individualized treatment decisions based on molecular testing (so-called precision medicine). As in previous years, close cooperation with representatives from patient organizations from around the world is an important aspect of the ABC conference. This cooperation was reinforced and expanded at the ABC4 conference. A global alliance was founded at the conclusion of the consensus conference, which aims to promote and coordinate the measures considered necessary by patient advocates worldwide. Because the panel of experts was composed of specialists from all over the world, it was inevitable that the ABC consensus also reflected country-specific features. As in previous years, a team of German breast cancer specialists who closely followed the consensus voting of the ABC panelists in Lisbon and intensively discussed the votes has therefore commented on the consensus in the context of the current German guidelines on the diagnosis and treatment of breast cancer 1 , 2 used in clinical practice in Germany. The ABC consensus is based on the votes of the ABC panelists in Lisbon.
由法蒂玛·卡尔多索教授牵头的第四届晚期乳腺癌(ABC)诊断与治疗国际共识会议(ABC4)于2017年11月2日至4日在里斯本再次召开。为简化起见,下文将使用缩写ABC。在临床实践中,该缩写对应转移性乳腺癌或局部晚期疾病。今年的重点是ABC治疗的新进展。讨论的主题包括细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制在激素受体(HR)阳性ABC中的重要性、双抗体阻断治疗HER2阳性ABC的应用、三阴性ABC中的聚(ADP-核糖)聚合酶(PARP)抑制以及潜在的治疗效果。会议讨论的另一个主要领域是BRCA相关乳腺癌、脑转移的治疗以及基于分子检测的个体化治疗决策(即所谓的精准医学)。与往年一样,与来自世界各地患者组织代表的密切合作是ABC会议的一个重要方面。这种合作在ABC4会议上得到了加强和扩展。在共识会议结束时成立了一个全球联盟,旨在促进和协调全球患者倡导者认为必要的措施。由于专家小组由来自世界各地的专家组成,ABC共识不可避免地也反映了各国的特点。因此,与往年一样,一组德国乳腺癌专家密切关注了在里斯本的ABC小组成员的共识投票,并深入讨论了这些投票结果,他们在德国临床实践中使用的乳腺癌诊断和治疗现行德国指南的背景下对该共识发表了评论。ABC共识基于在里斯本的ABC小组成员的投票。